Randomised, controlled trial with the trypsin-modified inactivated poliovirus vaccine: Assessment of intestinal immunity with live challenge virus

Vaccine

Volumn 17, Issue 9-10, 1999, Pages 1084-1090

  Piirainen, Liisa ^a   Stenvik, Mirja ^a   Roivainen, Merja ^a   Eskola, Juhani ^a   Beuvery, E Coen ^b   Hovi, Tapani ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Intestinal immunity; Poliovirus vaccine; Trypsin modification

Indexed keywords

LIVE VACCINE; POLIOMYELITIS VACCINE;

ACTIVE IMMUNIZATION; ANTIBODY RESPONSE; ARTICLE; DRUG POTENCY; HUMAN; IMMUNOGENICITY; INFANT; INTESTINE MUCOSA; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; POLIOMYELITIS; PRIORITY JOURNAL;

ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNITY, MUCOSAL; INFANT; MALE; POLIOVIRUS; POLIOVIRUS VACCINE, INACTIVATED; TRYPSIN; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 0033525752     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00325-9     Document Type: Article

References (30)

1. Melnick J.L. Advantages and disadvantages of killed and live poliomyelitis vaccines. Bull. WHO. 56:1978;21-38.
2. Ogra P.L., Faden H.S. Poliovirus vaccines: live or dead. J. Pediatr. 108:1986;1031-1033.
3. McBean A.M., Thoms M.L., Albrecht P., Cuthie J.C., Bernier R. The serologic response to oral polio vaccine and enhanced potency inactivated polio vaccine. Am. J. Epidemiol. 128:1988;615-628.
4. Galazka A. Stability of vaccines. Geneva, WHO, EPI/GEN/89.8.
5. Hovi T. Remaining problems before eradication of poliomyelitis can be accomplished. In: Melnick JL, editors. Progress in Medical Virology. Basel: S. Krager, 1991. 38. p. 69-95.
6. Vidor E., Meschievitz C., Plotkin S. Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine. J. Infect. Dis. 16:1997;312-322.
7. Nkowane B.M., Wassilak S.C.F., Orenstein W.A., Bart K.J., Schonberger L.B., Hinman A.R., Kew O.M. Vaccine-associated paralyticpoliomyelitis, USA, 1973-1984. JAMA. 257:1987;1335-1340.
8. Faden H., Modlin J.F., Thoms M.L., McBean A.M., Ferdon M.B., Ogra P.L. Comparative evaluation of immunisation with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J. Infect. Dis. 162:1990;1291-1297.
9. Onorato I.M., Modlin J.F., McBean A.M., Thoms M.L., Losonsky G.A., Bernier R.H. Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J. Infect. Dis. 163:1991;1-6.
10. Modlin JF, Halsey NA, Thoms ML, Meschievitz CK, Patriarca PA and the Baltimore Area Polio Vaccine Study Group. Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine - live attenuated oral poliovirus vaccine immunisation schedules. J. Infect. Dis. 1997; 175(Suppl):S228-234.
11. Modlin J.F., Halsey N.A., Thoms M.L., Meschievitz C.K., Patriarca P.A. PA and the Baltimore Area Polio Vaccine Study Group. Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine - live attenuated oral poliovirus virus immunisation schedules. J. Infect. Dis. 175:(Suppl):1997;S228-234.
12. Hogle J.M., Chow M., Filman J. Three dimensional structure of poliovirus at 2.9 Å resolution. Science. 229:1985;1358-1365.
13. Minor P.D., Ferguson M., Evans D.M.A., Almond J.W., Icenogle J.P. Antigenic structure of poliovirus serotypes 1, 2 and 3. J. Gen. Virol. 67:1986;1283-1291.
14. Fricks C.E., Icenogle J.P., Hogle J.M. Trypsin sensitivity of the Sabin strain of type 1 poliovirus: cleavage sites in virions and related particles. J. Virol. 54:1985;856-859.
15. Icenogle J.P., Minor P.D., Ferguson M., Hogle J.M. Modulation of humoral response to a 12-amino acid site on the poliovirus virion. J. Virol. 60:1986;297-301.
16. Minor P.D., Ferguson M., Phillips A., Magrath D.I., Huovilainen A., Hovi T. Conservation in vivo of protease cleavage sites in antigenic sites of polioviruses. J. Gen. Virol. 68:1987;1857-1865.
17. Roivainen M., Hovi T. Intestinal trypsin can significantly modify antigenic properties of polioviruses: implications for the use of inactivated poliovirus vaccine. J. Virol. 61:1987;3749-3753.
18. Roivainen M., Huovilainen A., Hovi T. Antigenic modification of polioviruses by host proteolytic enzymes. Arch. Virol. 111:1990;115-126.
19. Roivainen M., Montagnon B., Chalumeau H., Murray M., Wimmer E., Hovi T. Improved distribution of antigenic site-specificity of poliovirus neutralising antibodies induced by a protease-cleaved immunogen in mice. J. Virol. 64:1990;559-562.
20. Roivainen M., Piirainen L., Hovi T. Persistence and class-specificity of neutralising antibody response induced by trypsin-cleaved type 3 poliovirus in mice. Vaccine. 11:1993;713-717.
21. Kersten G.F.A., Lantinga M., Hazendonk T., Beuvery E.C. Immunogenicity of trypsin treated type 2 and type 3 poliovirus in rats. Biologicals. 23:1995;179-183.
22. Piirainen L., Roivainen M., Litmanen L., Eskola J., Beuvery E.C., Hovi T. Immunogenicity of a pilot inactivated poliovirus vaccine with trypsin treated type 3-component. Vaccine. 15:1997;237-243.
23. Pipkin P.A., Wood D.J., Racaniello V.R., Minor P.D. Characterization of L cells expressing the human poliovirus receptor for the specific detection of polioviruses in vitro. J. Virol. Meth. 41:1993;333-340.
24. Hovi T., Roivainen M. Radiometric cytolysis inhibition assay (RACINA): a new rapid test for neutralising antibodies to intact and trypsin-cleaved poliovirus. J. Clin. Microbiol. 27:1989;709-715.
25. Zhaori G., Sun M., Ogra P. Characteristics of the immune response to poliovirus virion polypeptides after immunisation with live or inactivated polio vaccines. J. Infect. Dis. 158:1988;160-165.
26. Ferguson M., Wood D., Minor P.D. Antigenic structure of poliovirus in inactivated vaccines. J. Gen. Virol. 74:1993;685-690.
27. Roivainen M., Thoden C-J., Stenvik M., Pöyry T., Hovi T. Virus excretion and strain specific antibody responses after oral poliovaccine in previously immunised children. J. Med. Virol. 23:1987;249-256.
28. Leclerc C., Deriaud E., Mimic V., van der Werf S. Identification of a T-cell epitope adjacent to neutralisation antigenic site 1 of poliovirus type 1. J. Virol. 65:1991;711-718.
29. Faden H., Duffy L. Effect of concurrent viral infection on systemic and local antibody responses to live attenuated and enhanced-potency inactivated poliovirus vaccines. Am. J. Dis. Child. 146:1992;1320-1323.
30. Maldonado Y.A., Pena-Cruz V., de la Luz Sanchez M., Logan L., Blandon S., Cantwell M.F., Matsui S.M., Millan-Velasco F., Valdespino J.L., Sepulveda J. Host and viral factors affecting the decreased immunogenicity of Sabin type 3 vaccine after administration of trivalent oral polio vaccine to rural Mayan children. J. Infect. Dis. 175:1997;545-553.